PhilipDLemingMD
Oncology • Cincinnati, OHHematologic Oncology, Melanoma
Consultant Cincinnati Cancer Advisors Independent Oncology Second Opinion Program
Dr. Leming is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4746 Montgomery Rd.
Ste 201
Cincinnati, OH 45212Phone+1 513-731-2273Fax+1 513-731-2274
Education & Training
NIH Clinical CenterResidency, CANCER RESEARCH - CLINICAL ASSOCIATE, 1981 - 1983
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 1980 - 1981- University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1975 - 1979
University of Louisville School of MedicineClass of 1975
Certifications & Licensure
MD State Medical License 1981 - 2026
OH State Medical License 1977 - 2026
FL State Medical License 2022 - 2025
KY State Medical License 1997 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top MD Consumers Checkbook
Clinical Trials
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
- Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN) Start of enrollment: 2011 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 9278 citationsSafety, activity, and immune correlates of anti-PD-1 antibody in cancer.Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, Scott N. Gettinger, David Smith
The New England Journal of Medicine. 2012-06-27 - 277 citationsIpilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial.F. Stephen Hodi, Sandra J. Lee, David F. McDermott, Uma N. M. Rao, Lisa H. Butterfield
JAMA. 2014-11-05 - 903 citationsOverall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell...Scott N. Gettinger, Leora Horn, Leena Gandhi, David R. Spigel, Scott J. Antonia
Journal of Clinical Oncology. 2015-04-20
Journal Articles
- Prognostic Gene Expression Profiling in Cutaneous MelanomaDouglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology
Authored Content
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
- Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
Press Mentions
Meet Kentucky's Youngest Breast Cancer Patient: 'I Never Expected to Be Diagnosed with Cancer at 21'October 4th, 2024
Research History
- DIRECTOR OF CANCER RESEARCHTHE CHRIST HOSPITAL HEALTH NETWORK/ PREVIOUSLY THE CHRIST HOSPITAL1983 - 2019
Professional Memberships
- Member
- Member
- Member
- Member
- Member
- Society for Melanoma ResearchMember
- Pan-American Society for Pigment Cell ResearchMember
- The Royal Society of MedicineMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
